1 Humoral Response Dynamics Following Infection with SARS-CoV-2

Louis Grandjean MBBS^{1,2*}, Anja Saso MBBS^{2,3,4*}, Arturo Torres MSc^{1,5**}, Tanya Lam MBBS^{2**},
James Hatcher MBBS⁶, Rosie Thistlethwayte BA⁷, Mark Harris⁸, Timothy Best⁵, Marina
Johnson PhD¹, Helen Wagstaffe PhD¹, Elizabeth Ralph MSc⁹, Annabelle Mai MSc⁹, Caroline
Colijn PhD¹⁰, Judith Breuer MBBS¹, Matthew Buckland MBBS⁹, Kimberly Gilmour MBBS⁹,
David Goldblatt MB ChB¹ and the Co-Stars Study Team^{2†}

- 8 *Contributed equally (LG is also corresponding author)
- 9 **Contributed equally
- 10

11 Author Affiliations:

- 12
- ¹³ ¹Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of
- 14 Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
- 15 ²Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street,
- 16 London, WC1N 3JH
- ¹⁷ ³Department of Tropical and Infectious diseases; LSHTM, Keppel St, Bloomsbury, London
- 18 WC1E 7HT
- ⁴MRC Gambia at LSHTM, PO Box 273, Fajara, The Gambia
- 20 ⁵Department of Medicine, Imperial College, Paddington, London, W2 1NY
- ⁶Department of Microbiology, Great Ormond Street Hospital, Great Ormond Street, London,
 WC1N 3JH
- ²³ ⁷Management, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
- 24 ⁸Quality Improvement, Great Ormond Street Hospital, Great Ormond Street, London, WC1N
- 25 3JH
- ⁹Clinical Immunology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great
- 27 Ormond Street, London, WC1N 3JH
- 28 ¹⁰Department of Mathematics, Simon Fraser University, Vancouver, British Colombia,
- 29 Canada BC V5A
- 30

31 ***The Co-Stars Study Team:**

Dorcas Mirambe-Korsah	Fernanda Torrente	Jakub Wyszynski	Victoria Gander
Amy Leonard	Louise Myers	Aimee Vallot	Camille Paillas
Rose Fitzgerald	Adam Twigg	Rabia Manaf	Lois Gibbons
Hollie Powell	Richard Nar-Dorh	Ally Gray	Elias Fernandez
Aline Minja	Emily Beech	Waffa Girshab	Pei Shi Chia
Kate Webb	Malti Nakrani	Kim Gardiner	Valerija Karaluka
Karen Ryan	Dorothy Lee	Katie Groves	Hamad Khan
Shamime Nsubuga	Olivia Rosie Wilkinson	Julia Spires	Nuria Sanchez- Clemente
Sapriya Kaur	Natasha Carroll🛛	Jemma Efford	Gabriel Bredin
Celma Marisa Dos Santos Domingues?	Sophie Foxall	Helen Ashton	Abbey Afzal
Sally Mainland Maria Tabbu Dorothy Chikusu	Kate Crumpler Laura Chiverton Fariba Tahami	Lucinda Dawson Jade Sugars Baratth Samy	Claire Smith Jordan Mooney Shomona Begum

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Dhimple Patel	Philippa Wiltshire	Annie Susay	Anna Ryan
Luke Lancaster	Kavita Thind	Kate Speller	Rachel Sterling
Connor Tugulu	Sandhya Ghurburrun	Steffi Gray	Joy Mugas
Moe Kishma	Kathleen Akpokomua	a Sophie White	Eleana Pieri
Sabina Shamsad	Demi Alexandrou	Odera Aguele	
Anamika Jain	Subishma Gautam	Oliver Simms	

32

33 Corresponding author contact details:

- 34 Dr Louis Grandjean
- 35 Department of Infection, Inflammation and Immunity, Institute of Child Health, 30 Guilford
- 36 Street, London, WC1N
- 37 <u>l.grandjean@ucl.ac.uk</u>
- 38
- 39 Trial registration number: NCT04380896.
- 40
- 41 Key words: immunity, serology, antibody, ELISA, kinetics, neutralisation, SARS-CoV-2,
- 42 COVID-19, virus, nucleoprotein, spike protein
- 43
- 44
- 45
- 46

47 Abstract

- 48 **Objectives** To understand humoral dynamics following SARS-CoV-2 infection
- 49 **Design** Prospective Cohort Study
- 50 **Setting** Great Ormond Street Hospital (Central London Paediatric Hospital)
- 51 **Participants** 67 healthcare workers aged >18 years who provided monthly serial serological
- 52 samples from 29th April 2020 until 30th June 2020.
- 53 Main outcome measures The change in monthly serial antibody titers to SARS-CoV-2
- 54 nucleoprotein (N), spike protein and the receptor binding domain of the spike protein.
- 55 **Results** The mean estimated half-life of the nucleoprotein antibody was 52 days (95% CI 42-
- 56 65). The spike and RBD antibody had significantly longer mean half-lives of 81 days (95% CI

57 61-111) and 83 days (95% CI 55-137) respectively. An ACE-2 receptor competition assay

- 58 demonstrated significant correlation between the spike and RBD antibody titers and ACE2
- 59 receptor blocking in-vitro. The time to a negative nucleoprotein antibody test for 50% of
- 60 the seropositive population was predicted to be 195 days (95% Cl 163-236).

61 Conclusions After SARS-CoV-2 infection, the predicted half-life of nucleoprotein antibody 62 was 52 days with 50% of seropositives becoming seronegative to this antibody at 195 days. 63 Widely used serological tests that depend on the nucleoprotein antibody will therefore 64 underestimate the true prevalence of infection within a year following the majority of 65 infections.

- 66
- 67
- 68
- ~ ~

69

70

71 Introduction

72 Since appearing as a cluster of pneumonia cases in December 2019 in Wuhan, China, Coronavirus disease (COVID-19) has rapidly spread worldwide.[1] As of July 7th, there have 73 74 been 11,863,477 cases, resulting in 544,949 deaths and a global health crisis, with 75 significant social, economic and public health implications.[2] COVID-19 is caused by severe 76 acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an enveloped RNA β -77 coronavirus.[3] Specific immunoglobulin (IgG) antibody responses to the SARS-CoV-2 78 trimeric spike (S) protein, nucleoprotein (N) protein and the receptor-binding domain 79 (RBD) develop between 6-15 days following disease-onset.[4] The S-protein, which contains 80 the RBD, binds to host cells via the angiotensin-converting-enzyme-2 (ACE-2) receptor, and 81 membrane fusion occurs before viral entry. [5,6] The N-protein plays an important role in transcription enhancement and viral assembly.[7] 82

83

84 The dynamics and duration of the antibody response to S-protein, N-protein and the RBD 85 following infection or exposure with SARS-CoV-2 remain poorly understood.[8–10] 86 Quantifying the humoral response shortly after infection limits the inferences that can be 87 made about longer term dynamics. SARS-CoV-2-specific antibodies (particularly to the S-88 protein) detected in convalescent individuals have been shown to strongly correlate with 89 virus-specific T-cell responses and viral neutralisation in vitro, as well as protection against 90 disease in animal models, following passive transfer of selected monoclonal 91 antibodies.[8,11–15] It is unknown whether re-infection in humans occurs following primary 92 infection with SARS-CoV-2. However, re-infection did not occur in rhesus macaques that 93 were re-challenged in the presence of detectable endogenous antibodies.[16,17] Taken

94 together, these findings highlight the importance of characterising humoral dynamics
95 following SARS-CoV-2 infection.

96 A large seroprevalence survey undertaken in Spain, recently reported a SARS-CoV-2 97 seroprevalence of 5.0%[18]. This study used a chemiluminescent assay to detect 98 nucleoprotein antibody together with a point of care lateral flow device. In contrast, Public 99 Health England undertook a SARS-CoV-2 spike antibody seroprevalence survey of 1000 100 samples from blood donors in London estimating a seroprevalence of 17.5% in the first 101 week of April[19]. Whilst many socio-demographic factors could account for the different 102 estimates of seroprevalence between these studies, one explanation may be the relative 103 decay of the spike and the nucleoprotein antibodies.

104

Longitudinal serological data from Taiwan's national SARS database estimated the half-life of SARS-CoV-1 neutralizing antibody to be 45 days, [20] whilst 74% of hospitalized patients in China had detectable SARS-CoV-1 IgG at 36 months post-infection.[21] After paucisymptomatic MERS infection, antibodies rapidly decayed and were undetectable within one year.[22] However, following severe disease, antibodies have been detected up to 34 months post-infection.²³

111

In order to evaluate SARS-CoV-2 antibody kinetics and longevity, we launched the Covid-19 Staff Testing of Antibody Responses Study (Co-STARS), a longitudinal prospective cohort study of healthcare workers designed to measure serial quantitative antibody levels over 1year. In parallel with serological data, detailed demographic, clinical and socioeconomic data was also collected across different hospital departments, to provide a comprehensive insight into factors that may influence antibody dynamics.

121 Methods

122

<u>Study setting and design</u>: Co-STARS is a 6-year single-centre, two-arm, prospective longitudinal cohort study of healthcare workers at a central London paediatric hospital (Great Ormond Street Hospital for Children). The study was approved to start by the United Kingdom NHS Health Research Authority on 29th April 2020 and registered on ClinicalTrials.gov (NCT04380896). Informed consent was obtained from all participants. The Study Protocol and Supplementary Materials submitted with this paper include detailed methods, power calculations and the data analysis approach.

130

131 <u>Study participants:</u> All hospital staff members ≥18 years of age were eligible for the study, 132 provided they did not display symptoms consistent with SARS-CoV-2 infection at 133 recruitment. If they had been symptomatic or had suspected contact with COVID-19 134 previously, at least 21 days were required to have passed prior to their baseline visit. Those 135 significantly immunosuppressed[23] or those who had previously received blood products 136 (including immunoglobulins or convalescent sera) since September 2019 were excluded 137 from the study.

138

<u>Data Collection:</u> After providing informed consent, participants undertook a detailed, standardised online questionnaire at study entry. This included socio-demographic factors, details of previous exposure to and symptomatic episodes consistent with COVID-19, any subsequent complications, previous SARS-CoV-2 diagnostic test results, past medical and contact history, and a comprehensive assessment of risk factors for exposure, susceptibility

144 to infection and severe disease. Blood samples were also taken at baseline and each follow-

145 up visit for determination of SARS-CoV-2 serology.

146

Measurement of SARS-CoV-2 serum antibody and viral RNA by PCR: All serological samples were analysed by the Meso Scale Discovery (MSD) Chemiluminescent binding assay that detects and quantifies anti-SARS-CoV-2 IgG specific for trimeric S-protein, RBD and Nprotein. All samples were run in parallel on the commercial ELISA EDI kit (Epitope Diagnostics Inc., California) that detects the anti-SARS-CoV-2 IgG to N-protein. The EDI kit did not quantify titers but did provide a positive, negative or equivocal test output with a ratio relative to the positive control.

154

155 An MSD[®] 96-well Custom Competition Assay designed to measure the inhibition of ACE-2 156 receptor binding to S or RBD by serum-derived antibody (MSD, Maryland) was run on 94 157 serial samples samples from 46 participants (two participants had 3 serial samples) in order 158 to establish *in vitro* correlates of functional immunity. IgG levels for the MSD assay were 159 expressed as arbitrary units calibrated against a set of reference sera distributed by the 160 National Institute of Biological Standards and Control (Potters Bar, UK) under the auspices of 161 the World Health Organisation. Assay gualification and performance were evaluated in our 162 laboratories (see Supplementary Materials).

163

SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction (RT-PCR) targeting
the N-gene was performed following RNA extraction, as previously described by colleagues
at our laboratory.[24]

167

168 Follow-Up Visits: All seropositive participants are being followed up monthly (ongoing) for 169 repeat antibody testing for the first 6 months then 6-monthly thereafter. Seronegative 170 participants will be followed up 6-monthly. At each follow-up visit, participants completed a 171 shortened version of the baseline questionnaire, focussing on any recurrent COVID-19 172 exposure and/or symptoms. 173 174 Study outcomes: The primary outcome of the study was to establish humoral dynamics 175 following SARS-CoV-2 infection. Secondary outcomes measures included the incidence of 176 SARS-CoV-2 re-infection, the dynamics of the cellular response, IgA dynamics and the clinical

177 and demographic factors that are associated with the rate of antibody decay.

178

179 <u>Statistical analysis:</u> Power calculations were based on log-linear regression using the 180 pwr.f2.test function in R for general linear models. We assumed a study power of 80% and 181 provided a study power for a variety of effect sizes and co-variates. We provided estimates 182 for the study size required to detect effect sizes of ~20% changes in log linear titers over 1 183 year with (with an alpha of 0.05) **(Supplementary Figure 1).**

184

We used a Bayesian framework to model antibody decay from 21 days post infection as a negative exponential (log-linear) function of time using a random intercepts mixed effects model, with random effects at the individual level to adjust for the titer variation between patients. The 21-day starting point for antibody decay was chosen *a-priori* based on existing data of antibody responses to SARS-CoV-2.[25] Plotting the rate of decay against time supported our hypothesis that the rate of the negative exponential decay would remain constant over time (**Supplementary Figure 2**).

192

193	Antibody titers were log-transformed and a linear model was fitted to the paired points
194	using RSTAN in R (R: A language and environment for statistical computing. Foundation for
195	Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ .).
196	
197	Variability in antibody titers was modelled by introducing a random effects parameter at the
198	level of the individual. Biologically important covariates that were hypothesized a-priori to
199	influence antibody titers, including age, sex, BMI, comorbidities and ethnicity, were
200	considered and the Deviance Information Criterion (DIC) was used to define the model of
201	best fit to the data. The prior for the slope was drawn from a normal distribution (mean=0,
202	variance=1), the intercept was a uniform distribution (min=0, max=10) while the random
203	effects were taken from a normal distribution (mean=0, sigma_u) where sigma_u was
204	estimated from the model.

205

The posterior probabilities of the slope were applied to infer the half-life distributions, using the following relationship between the half-life and the slope: $t_{1/2} = \ln(2)/r$ where r is the slope sampled from the posterior distribution and $t_{1/2}$ is the half-life.

209

The time to test negativity for 50% of the population, t_{neg50} , was defined as the time for the initial antibody titers (measured from 21 days after symptom-onset) to decline to the negative threshold value for the assay. The confidence limits around the curves were derived by repeated sampling from the posterior distribution of the starting titers (including their random effect offset) combined with repeated sampling from the posterior slopes.

215

216

217	Patient and Public Involvement: Participants were first invited to be involved in the research
218	by hospital wide e-mail via the GOSH communications department. Before the study was
219	undertaken, a survey was conducted by the trust that demonstrated the importance of this
220	research to the hospital staff. A subset of 30 participants was asked for their feedback
221	throughout the study preparation, design, implementation and analysis. This same group
222	were involved in determining the design and dissemination of results to all study
223	participants. Dissemination of the results will take place to all participants at the trust wide
224	level.

226 Results

227	Socio-Demographic and Clinical Details: A total of 137 longitudinal samples that were in
228	pairs or triplicate from 67 of the first participants in the Co-Stars study were available for
229	analysis. Fifty-three participants (79%) of the cohort were women and 25% were from Black,
230	Asian, Minority Ethnic (BAME) backgrounds (17/67). Importantly, none of the participants
231	had been admitted to hospital and only 5% had underlying comorbidities. Age, clinical, and
232	demographic variables for the cohort are reported in Supplementary Table 1.
233	
234	Model Fit: The combination of co-variates that provided the best model fit was determined
235	by optimizing the Deviance Information Criterion (Supplementary Table 2). Log-linear
236	models were fitted to the decay of each SARS-CoV-2 antibody with confidence limits on the
237	slope included with and without individual random effects (Figure 1). Monte Carlo Markov
238	Chain (MCMC) plots converged appropriately for the 3 antibodies and estimated parameters
239	(Supplementary Figure 3).
240	
241	

243 Half-life Estimations: The mean posterior probability of the slope of the N-antibody was 244 twice the magnitude of the mean slopes of the S and RBD antibodies (Supplementary Figure 245 **4).** This translated to a half-life of 52 days (95% CI 42-65) for the nucleoprotein antibody and 246 a half-life of 81 (95% CI 61-111) and 83 days (95% CI 55-137) for the S- and RBD-antibody, 247 respectively (Figure 2). 248 Time-to-Negativity: When these estimated rates were extrapolated to time-to-negativity 249 (Figure 3) and time-to-undetectable curves (Supplementary Figure 5), 50% of the 250 seropositive population by the MSD assay were estimated to be negative to the N-antibody 251 at 195 days (95% Cl 163-236); by comparison, 100% of subjects were estimated to remain 252 positive to the trimeric S-antibody at the same time point. 253 254 The time-to-negativity for 50% of the seropositive population for the RBD antibody was 255 predicted to be 260 days (95% CI 180-418) and for the trimeric S antibody was 532 days 256 (95% CI 418-667). However, the time-to-negativity was reduced to 67 days in the EDI assay 257 (95% CI 47-91) days. (Figure 3). 258 259 Association of Demographic Variables with Antibody Titers: Both BAME participants and 260 those >50 years were significantly associated with increased initial antibody titers. Neither 261 co-morbidities, sex nor BMI were significantly associated with increased antibody titers. 262 Interactions between age and time, sex and time and ethnicity and time were also examined

and none were significant (Supplementary Table 3 and Supplementary Figure 7).

- 264 <u>Competitive Binding Assay:</u> There was a strong positive linear correlation between ACE-2
- receptor blocking and both S-protein (R2=0.72, p<0.001) and RBD antibody titers (R2=0.77,
- 266 p<0.001) (Figure 4).

267 **Discussion**

268	This prospective study of antibody responses following SARS-CoV-2 infection has estimated
269	the mean half-life of the nucleoprotein (N) antibody to be only 52 days. Consequently, 50%
270	of seropositive individuals will have a negative N-antibody test at 195 days after the start of
271	antibody decay; by contrast 100% are predicted to have a positive test to the trimeric S-
272	antibody at the same time point.
273	
274	The half-life of the N-antibody was significantly shorter than that of the trimeric S- and RBD-

antibodies with a mean of 81 and 84 days, respectively. These findings have immediate implications for SARS-CoV-2 diagnostic testing particularly widely used serological tests that target N-antibodies. Our findings are consistent with published estimates of SARS-CoV and MERS-CoV humoral dynamics following mild-to-moderate infection.[9,20,22,26–28]

279

280 To date, no studies have comprehensively characterized the nature and duration of 281 antibody responses to different SARS-CoV-2 epitopes, stratified by demographic factors and 282 comorbidities. Long et al recently reported waning of SARS-CoV-2-specific IgG and 283 neutralizing antibodies within 2-3 months following infection, decreasing by up to 76% and 284 81%, respectively. This was more pronounced following clinical disease, although 40% of 285 asymptomatic patients (compared to 13% symptomatic) became seronegative in this early 286 convalescent period.[10] Detailed antibody kinetics, however, were not reported. 287 Asymptomatic or mildly symptomatic cohorts have also been largely overlooked, with most 288 studies conducted on hospitalized patients. Our study addresses these gaps, facilitated by 289 the MSD assay which enabled evaluation of absolute antibody titers to three major SARS-290 CoV-2 epitopes in parallel. Those participants over 50 years of age and BAME participants

had higher initial antibody titers to N, S and RBD antigens. Although elderly patients are
known to produce lower antibody responses to infection and vaccination, [29,30] increased
disease severity in this group may have influenced antibody response. The association
between ethnicity and antibody titers needs to be further explored.

295

296 None of the seropositive healthcare workers identified in this study required hospitalization. 297 This is important, given that only 1% of 20-30 year olds and 18% of >80 year olds diagnosed 298 COVID-19 cases are hospitalized, making our study population representative of the 299 majority of community SARS-CoV-2 infections.[31] Severe disease has been associated with 300 higher antibody titers and a longer duration of antibody response following both SARS and 301 MERS.[9,20,21,32] When long-term follow-up studies of hospitalized SARS-CoV-2 patients 302 are published, we therefore expect the half-life estimates to increase due to the increased 303 severity of initial disease.

304

Viral neutralization assays remain the gold-standard *in vitro* correlate of protection and the lack of formal neutralization tests is a limitation of the study. ACE-2 receptor competition assays such as the MSD competitive binding assay have been shown to correlate well with formal viral neutralization assays[33]. The ACE-2 competition assay used in this study had a strong positive linear correlation with both S-antibody titers (R²=0.72) and RBD-antibody titers (R²=0.77). Therefore, our observed decline in S-antibody titers is likely to be proportional to declines in functional receptor blocking activity.

312

313 Our negative exponential model of antibody decay assumed a constant rate of decay over 314 time. Negative exponential models of antibody decay are frequently used to model antibody

315 decay, [34,35] and this assumption was supported by plotting the rate of decay over time 316 (Supplementary Materials Fig.2). Nevertheless, increased serial antibody measurements 317 will enable us to test this hypothesis further and refine our half-life predictions accordingly. 318 Whilst the severity of infection among our study participants is likely to be representative of 319 community infection, our findings may be biased to healthcare workers. Moreover, a 320 population of paediatric healthcare workers are more likely to be repeatedly exposed to 321 seasonal CoV infection. We do not know to what extent this influences our measurements of the SARS-CoV-2 humoral response or our estimates of antibody decay. Recent studies 322 323 have hypothesized that previous exposure to CoVs may confer some protection against 324 SARS-CoV-2[36] and may need to be accounted for when modelling transmission or 325 longevity dynamics.[37] Results are conflicting, however, and it remains unclear if any cross-326 reactivity is T-cell or antibody mediated.[38-41] Stratifying the SARS-CoV-2 humoral 327 response by seasonal coronavirus titers will enable this potential bias to be understood.

328

329 Although all study participants had clinical symptoms that they attributed to COVID-19 330 (Supplementary Table 1) and at least one positive serological test, not all participants were 331 diagnosed by PCR testing. Despite our formal performance evaluation of the MSD assay 332 demonstrating a high sensitivity and specificity, it is theoretically possible that some of our 333 paired positive samples arose from repeated false positive tests. Our estimates of the time-334 to-negative test for 50% of the population (t_{neg50}) and the time-to-undetectable (t_{u50}) are 335 also dependent on the negative thresholds and lower limits of detection of the assay, 336 respectively. Serological assays with very high positive-negative discrimination and low 337 limits of detection will therefore detect antibody for longer. We repeated our analysis of N-

antibody on the EDI[™] assay which estimated an even lower t_{neg50} of 67 days (95% CI 47-91),
suggesting that our estimates of the half-life of the N-antibody are robust between assays.

340

341 Protective immunity is a complex dynamic of host, environmental and viral factors. It can be 342 difficult to disentangle the mechanisms underlying re-infection, including the role played by 343 viral escape (i.e. genetic drift) versus weak or waning immune responses.[42] To date, no 344 definitive quantitative or qualitative correlate-of-protection has been identified for SARS-345 CoV-2 infection, disease or onward transmission.[9,43] This hampers our understanding of 346 the functional and clinical significance of waning antibodies (particularly N-antibody) 347 observed in this study. Recent findings from animal studies support the role of neutralizing 348 antibodies as a correlate of immunity.[11,16,17] Similarly, a controlled human infection 349 model of seasonal CoV 229E demonstrated waning of IgG-specific antibodies within 1 year, 350 with subsequent reinfection of 6/9 individuals upon homologous viral challenge, albeit 351 without clinical symptoms. [44] If reinfection does occur, severity of disease may therefore 352 be attenuated, unless antibody-dependent disease enhancement by sub-neutralising 353 antibody titers occurs.[42]

354

Furthermore, robust memory T-cell responses to specific SARS-CoV-2 peptides are elicited following infection; this also includes seronegative and/or pauci-symptomatic individuals.[15,40,41] As such, anamnestic cell-mediated immune responses may prevent clinically significant re-infection, in keeping with other viral pathogens such as measles and hepatitis A. Prospective evaluation of re-infection alongside T-cell, B-cell and mucosal IgA dynamics should therefore be an urgent priority. The long-term data generated by the Co-

361 STARS study during the predicted future waves of the pandemic will be particularly 362 informative.

363

364 In summary, this prospective cohort study of 137 longitudinally collected serological 365 samples from 67 healthcare workers at Great Ormond Street Hospital has estimated that, in 366 contrast to S-antibody, the half-life of IgG to N-antigen is only 52 days. Fifty percent will 367 therefore have negative N-antibodies 195 days after the start of antibody decay. This has 368 significant implications for sero-prevalence surveys that are based on the measurement of 369 IgG to N-antigen in order to understand the spread of SARS-CoV-2 within the population. 370 Data of this kind directly informs public health policy and responses to future waves of the 371 pandemic. Policymakers relying on these estimates at a population level may need to be 372 cautious, allowing for possible underestimation of the true prevalence of previous SARS-373 CoV-2 infection and/or exposure. Conversely, the trimeric S-antibody correlated strongly 374 with ACE-2 receptor blockade and persisted longer with 50% of seropositive participants 375 estimated to still test positive at 532 days ($t_{1/2}$ 81 days). This is reassuring for post-vaccine 376 licensure surveillance studies, given that current vaccine candidates are based on 377 recombinant or fragments of S-protein.[45] Our upper bound for any detectable antibodies 378 (S, RBD or N) following mild-to-moderate infection was 1495 days.

379

380 Acknowledgements

We would like to dedicate this article to the staff members who died of COVID-19 at Great Ormond Street Hospital during the first wave of the pandemic. We would also like to thank all the staff at Great Ormond Street Hospital who have taken part in the study. In addition, we are very grateful for all the hard work undertaken by the Great Ormond Street laboratory staff and the staff in the immunology laboratories both in the Camelia Botnar

386	Laboratory and the Great Ormond Street Institute of Child Health who ensured that all the
387	PCR tests and serological assays were completed in a timely manner. Finally, we would like
388	to acknowledge the support of the Great Ormond Street Hospital Research & Development,
389	Governance, Finance, Management, Estates, Operations and Communications departments.
390	
391	Author contributions
392	The first draft of the manuscript was prepared by: LG, AS, AT, TL, JH, RT, MH, TB, MJ, HW,
393	ER, AM, CC, JB, KG, DG
394	
395	The study was designed and implemented by:
396	LG, AS, AT, TL, JH, RT, MH, TB, MJ, HW, ER, AM, CC, JB, KG, DG & the Co-Stars Team.
397	
398	Testing for SARS-CoV-2 RNA and antibody was conducted by: LG, AS, AT, TL, JH, RT, MH, TB,
399	MJ, HW, ER, AM, CC, JB, KG, DG
400	
401	
402	Funding statement
403	In line with UK government policy GOSH NHS Trust made the first diagnostic test available
404	to all staff members in the hospital either as part of the study or outside the study. The
405	GOSH charity provided the funding for follow up testing over the first 6 months of the study.
406	LG declares funding from Wellcome Post-Doctoral Research Fellowship (201470/Z/16/Z). AS
407	declares funding from Wellcome Trust Global Health Clinical Ph.D. Fellowship
408	(220565/Z/20/Z). GOSH NHS Trust hosts a NIHR Funded Biomedical Research Centre which
409	provides infrastructure support permitting translational research.

412 **Competing interests' statement**

413 All authors have completed the ICMJE uniform disclosure form at 414 http://www.icmje.org/coi disclosure.pdf and declare: no support from any organisation for 415 the submitted work; no financial relationships with any organisations that might have an 416 interest in the submitted work in the previous three years, no other relationships or 417 activities that could appear to have influenced the submitted work.

418

419 Exclusive License

420 The Corresponding Author has the right to grant on behalf of all authors and does grant on 421 of behalf all authors, а worldwide licence 422 (http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.do 423 c) to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether 424 known now or created in the future), to i) publish, reproduce, distribute, display and store 425 the Contribution, ii) translate the Contribution into other languages, create adaptations, 426 reprints, include within collections and create summaries, extracts and/or, abstracts of the 427 Contribution and convert or allow conversion into any format including without limitation 428 audio, iii) create any other derivative work(s) based in whole or part on the on the 429 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently 430 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links 431 from the Contribution to third party material where-ever it may be located; and, vi) licence 432 any third party to do any or all of the above. All research articles will be made available on 433 an open access basis (with authors being asked to pay an open access fee-see 434 http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-

checklists/copyright-open-access-and-permission-reuse). The terms of such open access
shall be governed by a Creative Commons licence—details as to which Creative Commons
licence will apply to the research article are set out in our worldwide licence referred to
above.

439

440 **Transparency Statement**

The lead author affirms that the manuscript is an honest, accurate, and transparent account
of the study being reported; that no important aspects of the study have been omitted; and

- that any discrepancies from the study as planned (and, if relevant, registered) have been
- 444 explained.
- 445

446 **References**

- 447 1 Guan W, Ni Z, Hu Y, *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China.
 448 *New England Journal of Medicine* 2020;**382**:1708–20. doi:10.1056/NEJMoa2002032
- 449 2 Johns Hopkins University. Coronavirus COVID-19 Global Cases by the Center for Systems
 450 Science and Engineering (CSSE) at Johns Hopkins University (JHU).
- 3 Zhu N, Zhang D, Wang W, *et al.* A novel coronavirus from patients with pneumonia in
 China, 2019. *New England Journal of Medicine* 2020;**382**:727–33.
- 453 doi:10.1056/NEJMoa2001017
- 454 4 Immune responses and immunity to SARS-CoV-2. https://www.ecdc.europa.eu/en/covid-455 19/latest-evidence/immune-responses (accessed 4 Jul 2020).
- 456 5 Ou X, Liu Y, Lei X, *et al.* Characterization of spike glycoprotein of SARS-CoV-2 on virus
 457 entry and its immune cross-reactivity with SARS-CoV. *Nature Communications*458 2020;**11**:1–12. doi:10.1038/s41467-020-15562-9
- 459 6 Walls AC, Park Y-J, Tortorici MA, *et al.* Structure, Function, and Antigenicity of the SARS460 CoV-2 Spike Glycoprotein. *Cell* 2020;**181**:281-292.e6. doi:10.1016/j.cell.2020.02.058
- 461 7 Cong Y, Ulasli M, Schepers H, *et al.* Nucleocapsid Protein Recruitment to Replication 462 Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle. *Journal of* 463 *Virology* 2019;**94**. doi:10.1128/jvi.01925-19
- 464 8 Wang X, Guo X, Prof A, *et al.* Neutralizing Antibodies Responses to SARS-CoV-2 in COVID465 19 Inpatients and Convalescent Patients. *medRxiv* 2020;:2020.04.15.20065623.
 466 doi:10.1101/2020.04.15.20065623
- Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
 mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and
 association of antibody responses with severity of disease. medRxiv
- 470 2020;:2020.04.14.20065771. doi:10.1101/2020.04.14.20065771
- 471 10 Long Q-X, Tang X-J, Shi Q-L, *et al.* Clinical and immunological assessment of
 472 asymptomatic SARS-CoV-2 infections. *Nature Medicine* 2020;:1–5. doi:10.1038/s41591473 020-0965-6
- Rogers TF, Zhao F, Huang D, *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies
 and protection from disease in a small animal model. *Science (New York, NY)* Published
 Online First: 15 June 2020. doi:10.1126/science.abc7520
 - 22

477 12 Mehul Suthar AS, Zimmerman MG, Kauffman RC, et al. Rapid Generation of Neutralizing

- 478 Antibody Responses in COVID-19 Patients. *Cell Reports Medicine* 2020;**1**:100040.
- 479 doi:10.1016/j.xcrm.2020.100040
- Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human
 Coronaviruses. Trends in Immunology. 2020;41:355–9. doi:10.1016/j.it.2020.03.007
- 14 Ni L, Ye F, Cheng M-L, *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular
 Immunity in COVID-19 Convalescent Individuals Highlights d SARS-CoV-2-specific
 antibodies are detected in COVID-19 convalescent subjects II Detection of SARS-CoV-2Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity*2020;52:971-977.e3. doi:10.1016/j.immuni.2020.04.023
- 487 15 Sekine T, Perez-Potti A, Rivera-Ballesteros O, *et al.* Robust T cell immunity in
 488 convalescent individuals with asymptomatic or mild COVID-19. *bioRxiv*489 2020;:2020.06.29.174888. doi:10.1101/2020.06.29.174888
- 490 16 Munster V, Feldmann F, Williamson B, *et al.* Respiratory disease and virus shedding in
 491 rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* 2020;:2020.03.21.001628.
 492 doi:10.1101/2020.03.21.001628
- 493 17 Bao L, Deng W, Gao H, *et al.* Reinfection could not occur in SARS-CoV-2 infected rhesus
 494 macaques. *bioRxiv* 2020;:1–20. doi:10.1101/2020.03.13.990226
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, *et al.* Prevalence of SARS-CoV-2 in Spain
 (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet*2020;:S0140673620314835. doi:10.1016/S0140-6736(20)31483-5
- 498 19 Sero-surveillance of COVID-19. GOV.UK.
- https://www.gov.uk/government/publications/national-covid-19-surveillance reports/sero-surveillance-of-covid-19 (accessed 8 Jul 2020).
- 501 20 Ho MS, Chen WJ, Chen HY, *et al.* Neutralizing antibody response and SARS severity. 502 *Emerging Infectious Diseases* 2005;**11**:1730–7. doi:10.3201/eid1111.040659
- 503 21 Cao W-C, Liu W, Zhang P-H, *et al.* Disappearance of Antibodies to SARS-Associated
 504 Coronavirus after Recovery. *New England Journal of Medicine* 2007;**357**:1162–3.
 505 doi:10.1056/NEJMc070348
- 50622Choe P, Perera R, Park W, et al. MERS-CoV antibody responses 1 year after symptom507onset, South Korea, 2015. ncbi.nlm.nih.gov
- 508 23 Public Health England. Chapter 6: Contraindications and special considerations. In: *The* 509 *Green Book: Immunisation against infectious disease*. 2017.
- 510 24 Brown JR, Atkinson L, Shah D, *et al.* Validation of an extraction-free RT-PCR protocol for
 511 detection of SARS-CoV2 RNA. *medRxiv* 2020;:2020.04.29.20085910.
- 512 doi:10.1101/2020.04.29.20085910

513 25 Hou H, Wang T, Zhang B, *et al.* Detection of IgM and IgG antibodies in patients with

- 514 coronavirus disease 2019. *Clinical and Translational Immunology* 2020;**9**.
- 515 doi:10.1002/cti2.1136
- Alshukairi AN, Khalid I, Ahmed WA, *et al.* Antibody response and disease severity in
 healthcare worker MERS survivors. *Emerging Infectious Diseases* 2016;**22**:1113–5.
 doi:10.3201/eid2206.160010
- 519 27 Cao WC, Liu W, Zhang PH, *et al.* Disappearance of antibodies to SARS-associated
 520 coronavirus after recovery [18]. New England Journal of Medicine. 2007;**357**:1162–3.
 521 doi:10.1056/NEJMc070348
- Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute
 respiratory syndrome. *Emerging Infectious Diseases* 2007;**13**:1562–4.
 doi:10.3201/eid1310.070576
- 525 29 Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nature 526 Reviews Immunology. 2009;**9**:185–94. doi:10.1038/nri2508
- 30 Boraschi D, Italiani P. Immunosenescence and vaccine failure in the elderly: Strategies
 for improving response. *Immunology Letters* 2014;**162**:346–53.
 doi:10.1016/j.imlet.2014.06.006
- 530 31 Verity R, Okell LC, Dorigatti I, *et al.* Estimates of the severity of coronavirus disease
 531 2019: a model-based analysis. *The Lancet Infectious diseases* 2020;**0**.
 532 doi:10.1016/S1473-3099(20)30243-7
- 533 32 Payne DC, Iblan I, Rha B, *et al.* Persistence of antibodies against middle east respiratory
 534 syndrome coronavirus. *Emerging Infectious Diseases* 2016;**22**:1824–6.
 535 doi:10.3201/eid2210.160706
- A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on antibody-mediated
 blockage of ACE2-spike (RBD) protein-protein interaction. Published Online First: 23
 April 2020. doi:10.21203/rs.3.rs-24574/v1
- Antia A, Ahmed H, Handel A, *et al.* Heterogeneity and longevity of antibody memory to
 viruses and vaccines. *PLOS Biology* 2018;**16**:e2006601.
 doi:10.1371/journal.pbio.2006601
- 54235Balelli I, Pasin C, Prague M, et al. A model for establishment, maintenance and543reactivation of the immune response after vaccination against Ebola virus. Journal of
- 544 *Theoretical Biology* 2020;**495**:110254. doi:10.1016/j.jtbi.2020.110254
- 54536Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2546infection. Nature Communications 2020;11:1–6. doi:10.1038/s41467-020-16256-y
- 547 37 Kissler SM, Tedijanto C, Goldstein E, *et al.* Projecting the transmission dynamics of SARS548 CoV-2 through the postpandemic period. *Science* 2020;:eabb5793.
 549 doi:10.1126/science.abb5793

550 551	38	Ng K, Faulkner N, Cornish G, <i>et al.</i> Pre-existing and de novo humoral immunity to SARS- CoV-2 in humans. <i>bioRxiv</i> 2020;:2020.05.14.095414. doi:10.1101/2020.05.14.095414
552 553 554	39	Lv H, Wu NC, Tak-Yin Tsang O, <i>et al.</i> Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections II Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. <i>CellReports</i> 2020; 31 :107725.
555 556 557 558	40	Dong T, Peng Y, Mentzer AJ, <i>et al.</i> Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. <i>bioRxiv</i> 2020;:2020.06.05.134551. doi:10.1101/2020.06.05.134551
559 560 561	41	Grifoni A, Weiskopf D, Ramirez SI, <i>et al.</i> Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. <i>Cell</i> 2020; 181 :1489. doi:10.1016/j.cell.2020.05.015
562 563 564	42	Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. <i>Journal of General Virology</i> 2020;:jgv001439. doi:10.1099/jgv.0.001439
565 566 567	43	Melgaço JG, Azamor T, Ano Bom APD. Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection? Cellular Immunology. 2020; 353 :104114. doi:10.1016/j.cellimm.2020.104114
568 560	44	Callow' KA, Parry2 HF, Sergeant1 M, <i>et al.</i> The time course of the immune response to

- solar in callour initial coronavirus infection of man The change in the concentration of total IgA
 and protein in nasal. 1990.
- 571 45 Callaway E. The race for coronavirus vaccines: a graphical guide. *Nature* 2020;**580**:576–
 572 7. doi:10.1038/d41586-020-01221-y
- 573
- 574 Figure Legends
- 575
- 576 Figure 1

577 Bayesian log-linear model fits for the decay of the nucleoprotein (N) antibody, the trimeric 578 spike (S) antibody and the receptor binding domain (RBD) antibody from 21 days 579 following symptom onset. Confidence limits on the slope without individual random 580 effects are plotted in dark grey, with individual effects light grey. Red dotted line 581 represents the limit of seropositivity

582

583 Figure 2

- 584 Posterior probability for the distribution of the half-life taken from the start of antibody
- decay at 21 days for the nucleoprotein (N) (CoV.2.N green) antibody, the spike (S) protein
- antibody (Co.V.2.S red) and the RBD antibody (CoV.2.RBD blue).

- 588 **Figure 3**
- 589 A) Time-to-negativity curve by the MSD assay for the nucleoprotein (N) antibody (green),
- 590 the spike (S) antibody (red) and the receptor binding domain (RBD) antibody (blue).
- 591 B) Time-to-negativity curve by the EDI assay for the nucleoprotein (N) antibody (green).
- 592 Note: The EDI assay only measures the N-antibody.
- 593
- 594 **Figure 4**
- 595 The correlation of Spike and RBD antibody titers with ACE-2 receptor blocking.
- 596
- 597
- 598





Time from symptom onset



Time (days) to 1/2 life

CoV.2.S — CoV.2.N — CoV.2.RBD



Days from symptom onset



CoV.2.RBD



log(titer)

log(titer)